DaVita (DVA) Reports Q2: Everything You Need To Know Ahead Of Earnings
Article excerpt
Highlighted: the sentence this signal was extracted from
Dialysis provider DaVita Inc. (NYSE:DVA) will be reporting earnings this Tuesday afternoon. Here's what you need to know. DaVita beat analysts' revenue expectations last quarter, reporting revenues of $3.42 billion, up 6% year on year. It was a very strong quarter for the company, with a beat of analysts' EPS estimates and a solid beat of analysts' full-year EPS guidance estimates. Is DaVita a buy or sell going into earnings? Read our full analysis here, it's free for active Edge members. This quarter, the market is expecting DaVita's revenue to grow 3.5% year on year, slowing from the 6.1% increase it recorded in the same quarter last year. Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business will stay the course heading into earnings. DaVita rarely misses Wall Street's revenue estimates. Looking at DaVita's peers in the healthcare providers & services segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Centene delivered year-on-year revenue growth of 9.9%, beating analysts' expectations by 13.1%, and Tenet Healthcare reported revenues up 6.8%, topping estimates by 3.9%. Centene traded down 3.5% following the results while Tenet Healthcare was up 17.2%. Read our full analysis of Centene's results here and Tenet Healthcare's results here...
Keep reading with a free account
The rest of this article, and every signal for DaVita, is in your free account.